A product available for prophylaxis against hepatitis B virus infection. HBIG is prepared from plasma containing high titers of anti-HBs and provides short-term protection (three to six months).

A medication that is given as a “post-exposure” treatment to prevent hepatitis B. This means that HBIG is given after a person has been exposed to potentially infected blood or infected bodily fluids, which can include but is not limited to - contact with blood or through a needlestick, infants born to infected women, and through sexual contact or close household contact with an infected person. HBIG is often used as a post-liver transplant treatment.

A medication given after a person is exposed to blood or bodily fluids that might be infected with hepatitis B virus. It helps stop infection before it takes hold.